Neogen (NEOG) | Financial Analysis & Statements
Neogen Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Feb 2026Income Metrics
Revenue
211.2M
Gross Profit
99.0M
46.88%
Operating Income
-3.3M
-1.56%
Net Income
-17.0M
-8.05%
EPS (Diluted)
$-0.08
Balance Sheet Metrics
Total Assets
3.4B
Total Liabilities
1.3B
Shareholders Equity
2.1B
Debt to Equity
0.60
Cash Flow Metrics
Operating Cash Flow
17.4M
Free Cash Flow
7.8M
Revenue & Profitability Trend
Quarter Income Flow
Feb 28, 2026
Annual Income Flow
2025
Neogen Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 894.7M | 924.2M | 822.4M | 527.2M | 468.5M |
| Cost of Goods Sold | 473.3M | 460.3M | 416.5M | 284.1M | 253.4M |
| Gross Profit | 421.4M | 463.9M | 406.0M | 243.0M | 215.1M |
| Gross Margin % | 47.1% | 50.2% | 49.4% | 46.1% | 45.9% |
| Operating Expenses | |||||
| Research & Development | 21.1M | 22.5M | 26.0M | 17.0M | 16.2M |
| Selling, General & Administrative | 402.0M | 382.8M | 342.4M | 167.3M | 124.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 423.1M | 405.2M | 368.4M | 184.4M | 140.9M |
| Operating Income | -1.7M | 58.7M | 37.5M | 58.6M | 74.2M |
| Operating Margin % | -0.2% | 6.3% | 4.6% | 11.1% | 15.8% |
| Non-Operating Items | |||||
| Interest Income | 3.1M | 6.4M | 3.2M | 1.3M | 1.7M |
| Interest Expense | 71.6M | 73.4M | 56.0M | 72.0K | 78.0K |
| Other Non-Operating Income | -3.6M | -5.9M | -6.8M | 322.0K | -515.0K |
| Pre-tax Income | -1.1B | -14.3M | -22.0M | 60.2M | 75.3M |
| Income Tax | -41.1M | -4.9M | 828.0K | 11.9M | 14.4M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 19.8% | 19.1% |
| Net Income | -1.1B | -9.4M | -22.9M | 48.3M | 60.9M |
| Net Margin % | -122.1% | -1.0% | -2.8% | 9.2% | 13.0% |
| Key Metrics | |||||
| EBITDA | 123.5M | 180.3M | 124.4M | 84.4M | 96.4M |
| EPS (Basic) | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 |
| EPS (Diluted) | $-5.03 | $-0.04 | $-0.12 | $0.45 | $0.57 |
| Basic Shares Outstanding | 216894861 | 216481878 | 188880836 | 107801094 | 107468304 |
| Diluted Shares Outstanding | 216894861 | 216481878 | 188880836 | 107801094 | 107468304 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Neogen Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 129.0M | 170.6M | 163.2M | 44.5M | 75.6M |
| Short-term Investments | 0 | 325.0K | 82.3M | 336.6M | 305.5M |
| Accounts Receivable | 153.4M | 173.0M | 153.3M | 99.7M | 91.8M |
| Inventory | 190.9M | 189.3M | 133.8M | 122.3M | 100.7M |
| Other Current Assets | 53.3M | 56.0M | 53.3M | 23.8M | 17.8M |
| Total Current Assets | 576.9M | 589.2M | 585.9M | 626.8M | 591.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 17.2M | 14.8M | 11.9M | 3.2M | 2.5M |
| Goodwill | 3.5B | 5.8B | 5.9B | 392.9M | 355.3M |
| Intangible Assets | 1.4B | 1.5B | 1.6B | 107.5M | 92.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 35.2M | 20.4M | 15.2M | 2.2M | 2.0M |
| Total Non-Current Assets | 2.9B | 4.0B | 4.0B | 366.1M | 328.7M |
| Total Assets | 3.4B | 4.5B | 4.6B | 992.9M | 920.2M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 79.6M | 83.1M | 76.7M | 34.6M | 23.9M |
| Short-term Debt | 19.3M | 2.4M | - | - | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 38.7M | 22.8M | 20.9M | - | - |
| Total Current Liabilities | 174.0M | 154.3M | 145.5M | 77.8M | 53.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 874.8M | 888.4M | 885.4M | - | - |
| Deferred Tax Liabilities | 280.9M | 326.7M | 353.4M | 17.0M | 21.9M |
| Other Non-Current Liabilities | 42.9M | 35.3M | 35.9M | 10.7M | 4.3M |
| Total Non-Current Liabilities | 1.2B | 1.3B | 1.3B | 27.7M | 26.2M |
| Total Liabilities | 1.4B | 1.4B | 1.4B | 105.6M | 79.8M |
| Equity | |||||
| Common Stock | 34.7M | 34.7M | 34.6M | 17.2M | 17.2M |
| Retained Earnings | -536.4M | 555.6M | 565.0M | 587.9M | 539.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.1B | 3.1B | 3.1B | 887.4M | 840.4M |
| Key Metrics | |||||
| Total Debt | 894.1M | 890.8M | 885.4M | 0 | 0 |
| Working Capital | 402.9M | 434.9M | 440.5M | 549.0M | 537.9M |
Balance Sheet Composition
Neogen Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -1.1B | -9.4M | -22.9M | 48.3M | 60.9M |
| Depreciation & Amortization | 125.7M | 121.2M | 90.5M | 24.1M | 21.0M |
| Stock-Based Compensation | 17.3M | 13.8M | 10.2M | 7.2M | 6.4M |
| Working Capital Changes | -4.5M | -83.6M | -25.1M | -367.0K | -3.2M |
| Operating Cash Flow | -1.0B | 23.2M | 40.6M | 72.1M | 84.5M |
| Investing Activities | |||||
| Capital Expenditures | -99.5M | -111.3M | -64.9M | -24.4M | -26.7M |
| Acquisitions | 0 | 0 | 11.7M | -38.7M | -50.8M |
| Investment Purchases | 0 | 0 | -12.5M | -415.9M | -792.7M |
| Investment Sales | 325.0K | 82.0M | 266.8M | 381.8M | 764.6M |
| Investing Cash Flow | -99.2M | -29.3M | 201.0M | -97.2M | -105.6M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 550.0M | - | - | - | - |
| Debt Repayment | -550.3M | 0 | -100.0M | 0 | 0 |
| Financing Cash Flow | -3.8M | -538.0K | -119.3M | -1.1M | -1.1M |
| Free Cash Flow | -46.4M | -76.2M | -24.7M | 43.6M | 54.4M |
| Net Change in Cash | -1.1B | -6.6M | 122.3M | -26.3M | -22.2M |
Cash Flow Trend
Neogen Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
865.00
Forward P/E
32.11
Price to Book
0.98
Price to Sales
2.36
PEG Ratio
14.79
Profitability Ratios
Profit Margin
-69.94%
Operating Margin
-1.56%
Return on Equity
-25.57%
Return on Assets
-0.61%
Financial Health
Current Ratio
3.92
Debt to Equity
37.82
Beta
1.97
Per Share Data
EPS (TTM)
$-2.80
Book Value per Share
$9.66
Revenue per Share
$4.01
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NEOG | 2.0B | 865.00 | 0.98 | -25.57% | -69.94% | 37.82 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Revvity | 9.7B | 45.77 | 1.46 | 3.22% | 8.45% | 46.87 |
| Icon plc | 9.0B | 15.52 | 0.94 | 6.27% | 7.40% | 38.26 |
| Charles River | 8.3B | 681.33 | 2.61 | -4.23% | -3.60% | 81.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.





